ANTI-FIBROTIC DRUG RECRUITING PATIENTS ACROSS THE COUNTRY FOR PHASE 2 CLINICAL TRIAL
July 4, 2016
Promedior is currently recruiting patients for the PROMOTE study, a phase 2 trial of PRM-151 in subjects with primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF.
PRM-151 is a recombinant form of pentraxin-2 (PTX-2), a protein that circulates in the blood stream that helps to regulate tissue repair. PTX-2 levels have been found to be lower in patients with MF and other fibrotic diseases like Idiopathic Pulmonary Fibrosis. In a Phase 2 trial of PRM-151 in myelofibrosis patients, reversal of fibrosis (thickening and scarring of connective tissue) in the bone marrow was accompanied by improved cytopenias (reduction in number of blood cells). In a Phase 1b trial in Idiopathic Pulmonary Fibrosis patients, PRM-151 was safe and well tolerated.
This trial is looking for patients across the country to try this drug. If you think you are a candidate, speak to your doctor about it or contact Promedior.